We are live on ! Find out more
ADAP

Adaptimmune Therapeutics
ADAP

Delisted

ADAP was delisted on the 27th of October, 2025.

Back to rankings

40 hedge funds and large institutions have $121M invested in Adaptimmune Therapeutics in 2016 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 10 increasing their positions, 10 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

7.02% more ownership

Funds ownership: 0% → 7.02% (+7%)

0% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 10

13% less funds holding

Funds holding: 46 → 40 (-6)

45% less capital invested

Capital invested by funds: $219M → $121M (-$98.5M)

45% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 11

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
40
Holders Change
-6
Holders Change %
-13.04%
% of All Funds
1%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
6
Increased
10
Reduced
10
Closed
11
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
VIA
Vident Investment Advisory
Georgia
+$579K
2
Renaissance Technologies
Renaissance Technologies
New York
+$558K
3
AFM
Anson Funds Management
Texas
+$495K
4
AG
Artal Group
Luxembourg
+$480K
5
AA
ALPS Advisors
Colorado
+$326K

Top Sellers

Rank Fund Capital Flow
1
PI
Putnam Investments
Massachusetts
-$3.15M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$2.99M
3
IHM
Iguana Healthcare Management
New York
-$959K
4
RG
Rathbones Group
United Kingdom
-$622K
5
Capital World Investors
Capital World Investors
California
-$578K
Name Holding Trade Value Shares
Change 		Change in
Stake
CLOS
26
Compagnie Lombard Odier SCmA
Switzerland
$233K – – –
JP Morgan Chase
27
JP Morgan Chase
New York
$137K +$61.2K +12,756 +60%
Creative Planning
28
Creative Planning
Kansas
$124K +$4.8K +1,000 +3%
State of New Jersey Common Pension Fund D
29
State of New Jersey Common Pension Fund D
New Jersey
$97K – – –
Geode Capital Management
30
Geode Capital Management
Massachusetts
$66K +$1.34K +280 +2%
Susquehanna International Group
31
Susquehanna International Group
Pennsylvania
$65K +$76.5K +15,941 New
NSEDCP
32
NJ State Employees Deferred Compensation Plan
New Jersey
$64K – – –
Zurich Cantonal Bank
33
Zurich Cantonal Bank
Switzerland
$60K -$491K -102,300 -87%
WS
34
Wedbush Securities
California
$56K +$66.6K +13,889 New
GT
35
Glenmede Trust
Pennsylvania
$35K -$5.64K -1,175 -12%
OAJ
36
Ogorek Anthony Joseph
New York
$7K – – –
Wells Fargo
37
Wells Fargo
California
$6K – – –
UBS Group
38
UBS Group
Switzerland
$3K -$11.7K -2,436 -76%
AIM
39
Acrospire Investment Management
Illinois
$2K +$1.92K +400 New
TRCT
40
Tower Research Capital (TRC)
New York
$1K -$5.99K -1,249 -81%
PI
41
Putnam Investments
Massachusetts
– -$3.15M -447,181 Closed
PC
42
Polar Capital
United Kingdom
– -$423K -60,000 Closed
NLVP
43
New Leaf Venture Partners
New York
– -$388K -55,008 Closed
AC
44
Ascend Capital
California
– -$353K -50,000 Closed
VEA
45
Virtus ETF Advisers
New York
– -$190K -26,974 Closed
CAM
46
Cormorant Asset Management
Massachusetts
– -$178K -25,307 Closed
Deutsche Bank
47
Deutsche Bank
Germany
– -$164K -23,349 Closed
TG
48
TLP Group
Illinois
– -$94K -13,311 Closed
GCP
49
GSA Capital Partners
United Kingdom
– -$83K -11,803 Closed
Morgan Stanley
50
Morgan Stanley
New York
– -$25K -3,570 Closed
1
2
3

ADAP Hedge Fund Activity: Q4 2016 in Review

40 of the 4,001 institutional investors tracked by Wall St. Rank reported a position in Adaptimmune Therapeutics (ADAP) for Q4 2016, worth a combined $121M — down 45% from $219M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of ADAP and 6 opened new positions — a net loss of 5 holders — while 10 trimmed existing stakes and 10 added.

The largest buyer was Vident Investment Advisory, adding an estimated $579K. The largest seller was Putnam Investments, exiting entirely with an estimated $3.15M sold.

  • 40 institutional investors held Adaptimmune Therapeutics (ADAP) as of Q4 2016, down from 46 in Q3 2016.
  • Funds reported $121M of Adaptimmune Therapeutics stock for Q4 2016, down 45% quarter-over-quarter.
  • 6 funds opened new Adaptimmune Therapeutics positions in Q4 2016 and 11 closed out, a net change of -5 holders.
  • The largest Adaptimmune Therapeutics buyer in Q4 2016 was Vident Investment Advisory, an estimated $579K added.
  • The largest Adaptimmune Therapeutics seller in Q4 2016 was Putnam Investments, an estimated $3.15M sold.

Based on aggregated 13F filings for Q4 2016.